Irritable Bowel Syndrome Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Irritable Bowel Syndrome Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight’s “Irritable Bowel Syndrome Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Irritable Bowel Syndrome, historical and forecasted epidemiology as well as the Irritable Bowel Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Irritable Bowel Syndrome Market by downloading the comprehensive report from DelveInsight @ Irritable Bowel Syndrome Treatment Market Size
Key Takeaways from the Irritable Bowel Syndrome Market Report
Gain a competitive edge in the Irritable Bowel Syndrome Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Irritable Bowel Syndrome Treatment Drugs
Irritable Bowel Syndrome Epidemiology Segmentation in the 7MM
Irritable Bowel Syndrome Market Insights
Irritable bowel syndrome (IBS) is a complex disorder characterized by motility dysfunction, visceral hypersensitivity, and various contributing factors including genetics, diet, and immune activation. Its diagnosis and management pose significant challenges globally. IBS manifests in diverse forms, classified by predominant stool texture, and imposes a substantial burden on healthcare systems worldwide. In the United States alone, direct medical costs associated with IBS reach up to USD 10 billion annually, exacerbated by high healthcare resource utilization and regional disparities in testing and treatment approaches.
Discover key developments and opportunities in the Irritable Bowel Syndrome Market. Click here to learn more from DelveInsight’s latest report @ Irritable Bowel Syndrome Market Size
Irritable Bowel Syndrome Marketed Drugs
VIBERZI (eluxadoline) is a new class of medication acting on local receptors in the gastrointestinal tract. It improves diarrhea and abdominal pain by interacting with mu- and delta opioid receptors in the intestine to slow gastrointestinal motility and reduce visceral pain. Activation of the mu-receptor reduces diarrhea, while antagonism of the delta-receptor enhances the analgesic activity and reduces the risk of constipation.
Linaclotide is a guanylate cyclase-C agonist that is thought to work in two ways based on nonclinical studies. It binds to the guanylate cyclase-C receptor locally within the intestinal epithelium. Activation of guanylate cyclase-C results in increased intestinal fluid secretion, accelerated transit, and a decrease in the activity of pain-sensing nerves in the intestine. In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS to treat adults with IBS-C. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA for treating adults with moderate-to-severe IBS-C.
Irritable Bowel Syndrome Emerging Drugs
RHB-102 is an investigational, once-daily, bi-modal release, oral formulation of ondansetron, a leading member of the family of 5-HT3 serotonin receptor inhibitors intended to treat nausea, vomiting, and diarrhea symptoms experienced in some people suffering from acute gastroenteritis, gastritis, and irritable bowel syndrome with diarrhea (IBS-D).
Blautix (MRx1234) is a single-strain live biotherapeutic product (LBP), being developed as a treatment for both IBS-C and IBS-D and has the potential to become the first-ever disease-modifying therapy suitable for all irritable bowel syndrome patients regardless of clinical subtype. Blautix has a unique metabolism, consuming hydrogen and producing acetate, which promotes bacterial cross-feeding of the microbiota increasing diversity and stability, two attributes that have been demonstrated to be decreased in patients with irritable bowel syndrome compared to healthy controls.
Irritable Bowel Syndrome Therapeutics Market
There are five drugs approved for irritable bowel syndrome in the United States, namely VIBERZI (eluxadoline), LINZESS (linaclotide), IBSRELA (tenapanor), TRULANCE (plecanatide), and XIFAXAN (rifaximin). Market access and reimbursement options can differ depending on regulatory status, the size of the target population, the setting of care, unmet needs, the magnitude of incremental benefit claims, and costs.
Download DelveInsight’s Irritable Bowel Syndrome Market report today and stay ahead in this rapidly evolving field. @ Irritable Bowel Syndrome Clinical Trials
Scope of the Irritable Bowel Syndrome Market Report
Download the report to understand which factors are driving Irritable Bowel Syndrome Market Trends @ Irritable Bowel Syndrome Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Irritable Bowel Syndrome Market Overview at a Glance
4 Epidemiology and Market Methodology
5 Executive Summary of Irritable Bowel Syndrome
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Patient Journey
9 Key Endpoints in Irritable Bowel Syndrome Clinical Trials
10 Emerging Therapies
11 Marketed Therapies
12 Irritable Bowel Syndrome: The 7MM Analysis
13 Market Access and Reimbursement
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/